IRON

IRON

USD

Disc Medicine Inc. Common Stock

$86.060+3.050 (3.674%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$83.010

Máximo

$87.125

Mínimo

$83.010

Volume

0.64M

Fundamentos da empresa

Capitalização de mercado

3.2B

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.43M

Bolsa de valores

NGM

Moeda

USD

Faixa de 52 semanas

Mínimo $30.82Atual $86.060Máximo $95.95

Notícias relacionadas

GlobeNewswire

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for

Ver mais
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Analyst Upgrades

Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target

Stifel analyst Stephen Willey reinstates Disc Medicine with a Buy and announces $125 price target.

Ver mais
Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target
GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for

Ver mais
Disc Medicine to Participate in Upcoming Investor Conferences
Analyst Upgrades

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115

Morgan Stanley analyst Sean Laaman maintains Disc Medicine with a Overweight and raises the price target from $90 to $115.

Ver mais
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.